Bokf, Na Amgen Inc Transaction History

Bokf, Na

$5.65 Billion
Q3 2024

A detailed history of Bokf, Na transactions in Amgen Inc stock. As of the latest transaction made, Bokf, Na holds 70,799 shares of AMGN stock, worth $20.2 Million. This represents 0.4% of its overall portfolio holdings.

Number of Shares

70,799

Previous 73,038 3.07%

Holding current value

$20.2 Million

Previous $22.8 Million 0.04%

% of portfolio

0.4%

Previous 0.41%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$309.38 - $337.38 $692,701 - $755,393	-2,239 Reduced 3.07%	70,799 $22.8 Million
Q2 2024 Aug 07, 2024	SELL	$262.75 - $319.31 $999,763 - $1.21 Million	-3,805 Reduced 4.95%	73,038 $22.8 Million
Q1 2024 May 15, 2024	SELL	$268.87 - $324.56 $257,577 - $310,928	-958 Reduced 1.23%	76,843 $21.8 Million
Q4 2023 Feb 14, 2024	SELL	$255.7 - $288.46 $494,523 - $557,881	-1,934 Reduced 2.43%	77,801 $22.4 Million
Q3 2023 Nov 14, 2023	SELL	$218.65 - $271.46 $1.89 Million - $2.35 Million	-8,639 Reduced 9.78%	79,735 $21.4 Million
Q2 2023 Aug 21, 2023	BUY	$214.27 - $253.37 $1.07 Million - $1.26 Million	4,978 Added 5.97%	88,374 $19.6 Million
Q1 2023 May 11, 2023	SELL	$225.79 - $275.2 $4.42 Million - $5.38 Million	-19,561 Reduced 19.0%	83,396 $20.2 Million
Q4 2022 Feb 13, 2023	SELL	$229.03 - $291.01 $1.48 Million - $1.88 Million	-6,445 Reduced 5.89%	102,957 $27 Million
Q3 2022 Nov 14, 2022	SELL	$224.46 - $253.15 $541,173 - $610,344	-2,411 Reduced 2.16%	109,402 $24.7 Million
Q2 2022 Aug 11, 2022	BUY	$230.71 - $256.74 $1.85 Million - $2.06 Million	8,034 Added 7.74%	111,813 $27.2 Million
Q1 2022 May 13, 2022	SELL	$219.27 - $242.57 $406,965 - $450,209	-1,856 Reduced 1.76%	103,779 $25.1 Million
Q4 2021 Mar 11, 2022	BUY	$198.88 - $227.6 $929,764 - $1.06 Million	4,675 Added 4.63%	105,635 $23.8 Million
Q3 2021 Nov 10, 2021	SELL	$212.27 - $248.7 $865,849 - $1.01 Million	-4,079 Reduced 3.88%	100,960 $21.5 Million
Q1 2021 Apr 21, 2021	SELL	$221.91 - $258.6 $2.76 Million - $3.21 Million	-12,423 Reduced 10.58%	105,039 $26.1 Million
Q4 2020 Feb 12, 2021	SELL	$216.38 - $257.67 $289,516 - $344,762	-1,338 Reduced 1.13%	117,462 $27 Million
Q3 2020 Oct 30, 2020	SELL	$234.65 - $260.95 $2.08 Million - $2.31 Million	-8,854 Reduced 6.94%	118,800 $30.2 Million
Q2 2020 Aug 12, 2020	BUY	$197.81 - $242.74 $1.68 Million - $2.06 Million	8,496 Added 7.13%	127,654 $30.1 Million
Q1 2020 May 13, 2020	BUY	$182.24 - $241.7 $2.61 Million - $3.46 Million	14,328 Added 13.67%	119,158 $24.2 Million
Q4 2019 Feb 12, 2020	BUY	$189.21 - $243.2 $154,773 - $198,937	818 Added 0.79%	104,830 $25.3 Million
Q3 2019 Nov 13, 2019	BUY	$174.11 - $208.62 $1.37 Million - $1.64 Million	7,867 Added 8.18%	104,012 $20.1 Million
Q2 2019 Aug 14, 2019	SELL	$166.7 - $195.41 $5.05 Million - $5.91 Million	-30,268 Reduced 23.94%	96,145 $17.7 Million
Q1 2019 May 15, 2019	BUY	$180.87 - $203.88 $761,100 - $857,927	4,208 Added 3.44%	126,413 $24 Million
Q4 2018 Feb 13, 2019	BUY	$178.4 - $208.25 $9.02 Million - $10.5 Million	50,559 Added 70.57%	122,205 $23.8 Million
Q3 2018 Nov 13, 2018	SELL	$185.29 - $208.89 $910,700 - $1.03 Million	-4,915 Reduced 6.42%	71,646 $14.9 Million
Q2 2018 Aug 13, 2018	SELL	$166.05 - $186.51 $1.42 Million - $1.6 Million	-8,567 Reduced 10.06%	76,561 $14.1 Million
Q1 2018 May 14, 2018	SELL	$169.43 - $198.0 $27,617 - $32,274	-163 Reduced 0.19%	85,128 $14.5 Million
Q4 2017 Feb 14, 2018	SELL	$168.79 - $188.59 $236,812 - $264,591	-1,403 Reduced 1.62%	85,291 $14.8 Million
Q3 2017 Nov 14, 2017	BUY	$167.29 - $191.0 $788,772 - $900,565	4,715 Added 5.75%	86,694 $16.5 Million
Q2 2017 Aug 14, 2017	BUY	N/A	81,979	81,979 $14.1 Million

Others Institutions Holding AMGN

# of Institutions

3,084

Shares Held

401M

Call Options Held

7.56M

Put Options Held

7.16M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $153B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bokf, Na, based on Form 13F filings with the SEC.

News

Stay updated on Bokf, Na with notifications on news.

Account